AngioDynamics Company Leadership

ANGO Stock  USD 9.64  0.18  1.90%   
AngioDynamics employes about 760 people. The company is managed by 34 executives with a total tenure of roughly 278 years, averaging almost 8.0 years of service per executive having 22.35 employees per reported executive. Analysis of AngioDynamics management performance can provide insight into the firm performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with AngioDynamics future performance.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AngioDynamics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. To learn how to invest in AngioDynamics Stock, please use our How to Invest in AngioDynamics guide.
Joseph DeVivo  CEO
CEO and President and Director
James Clemmer  CEO
President CEO, Director
Howard Donnelly  Chairman
Independent Chairman of the Board

AngioDynamics Return on Sales


AngioDynamics Management Team Effectiveness

The company has return on total asset (ROA) of (0.0283) % which means that it has lost $0.0283 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.09) %, meaning that it created substantial loss on money invested by shareholders. AngioDynamics' management efficiency ratios could be used to measure how well AngioDynamics manages its routine affairs as well as how well it operates its assets and liabilities. As of 2nd of June 2023, Return on Investment is likely to drop to -7.39. In addition to that, Return on Average Assets is likely to drop to -0.05. AngioDynamics Net Current Assets as percentage of Total Assets are very stable at the moment as compared to the past year. AngioDynamics reported last year Net Current Assets as percentage of Total Assets of 14.36. As of 2nd of June 2023, Tangible Assets Book Value per Share is likely to grow to 5.24, while Revenue to Assets are likely to drop 0.46.

AngioDynamics Quarterly Total Assets

542.85 Million

As of 2nd of June 2023, Weighted Average Shares is likely to drop to about 44.3 M. In addition to that, Weighted Average Shares Diluted is likely to drop to about 44.3 M

AngioDynamics Workforce Comparison

AngioDynamics is rated second in number of employees category among related companies. The total workforce of Health Care industry is presently estimated at about 30,760. AngioDynamics holds roughly 760 in number of employees claiming about 2.47% of equities under Health Care industry.

AngioDynamics Profit Margins

The company has Profit Margin (PM) of (0.11) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.07) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.07.

AngioDynamics Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific AngioDynamics insiders, such as employees or executives, is commonly permitted as long as it does not rely on AngioDynamics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, AngioDynamics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

AngioDynamics Benchmark Summation

The output start index for this execution was zero with a total number of output elements of sixty-one. AngioDynamics Price Series Summation is a cross summation of AngioDynamics price series and its benchmark/peer.

AngioDynamics Notable Stakeholders

An AngioDynamics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as AngioDynamics often face trade-offs trying to please all of them. AngioDynamics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting AngioDynamics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Joseph DeVivoCEO and President and DirectorProfile
James ClemmerPresident CEO, DirectorProfile
Howard DonnellyIndependent Chairman of the BoardProfile
Ben DavisSenior Vice President Business DevelopmentProfile
Chad CampbellSenior Vice President and General Manager, Vascular AccessProfile
David HelselSenior Vice President - Global OperationsProfile
Heather DanielsCariveauSenior Vice President-Human ResourcesProfile
Benjamin DavisSenior Vice President Business DevelopmentProfile
Barbara KucharczykSenior Vice President-Global OperationsProfile
Robert SimpsonSenior Vice President and General Manager, Peripheral VascularProfile
Michael GreinerCFO, Executive Vice PresidentProfile
Warren NighanSenior Vice President-Senior Vice President Quality & Regulatory AffairsProfile
Brent BoucherSenior Vice President and General Manager, Oncology/SurgeryProfile
Kim SeaburySenior Vice President Information TechnologyProfile
Gary BarrettSenior Vice President Quality and Regulatory AffairsProfile
Michael TrimarchiInterim CFO, VP and Global ControllerProfile
John SotoChief Commercial Officer and Executive VPProfile
Mark StephensSr. VP of Admin.Profile
Stephen TrowbridgeSr. VP, General Counsel and Assistant SecretaryProfile
Jeffrey GoldIndependent DirectorProfile
Steven LaporteIndependent DirectorProfile
Jan ReedDirectorProfile
Dennis MetenyIndependent DirectorProfile
Eileen AuenDirectorProfile
Wesley JohnsonIndependent DirectorProfile
Kevin GouldIndependent DirectorProfile
Sriram VenkataramanIndependent DirectorProfile
Karen LicitraIndependent DirectorProfile
David BurgstahlerIndependent DirectorProfile
Laura PiccininiVP InternationalProfile
Caitlin StefanikIR Contact OfficerProfile
Richard RosenzweigGen VPProfile
Christopher DaileyIR Contact OfficerProfile
Marna BronfenMooreVP HRProfile

About AngioDynamics Management Performance

The success or failure of an entity such as AngioDynamics often depends on how effective the management is. AngioDynamics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of AngioDynamics management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the AngioDynamics management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for 2023
Return on Investment(7.20) (7.39) 
Return on Average Assets(0.0432) (0.0466) 
Return on Average Equity(0.06) (0.06) 
Return on Invested Capital(0.21) (0.23) 
Return on Sales(0.08) (0.09) 
The data published in AngioDynamics' official financial statements usually reflect AngioDynamics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of AngioDynamics. For example, before you start analyzing numbers published by AngioDynamics accountants, it's critical to develop an understanding of what AngioDynamics' liquidity, profitability, and earnings quality are in the context of the Health Care Equipment & Supplies space in which it operates.
Please note, the presentation of AngioDynamics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, AngioDynamics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in AngioDynamics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of AngioDynamics. Please utilize our Beneish M Score to check the likelihood of AngioDynamics' management manipulating its earnings.

AngioDynamics Workforce Analysis

Traditionally, organizations such as AngioDynamics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare AngioDynamics within its industry.

AngioDynamics Manpower Efficiency

Return on AngioDynamics Manpower

Revenue Per Employee323.4K
Revenue Per Executive9.3M
Net Loss Per Employee41.2K
Net Loss Per Executive780.8K
Working Capital Per Employee90.8K
Working Capital Per Executive2M
Today, most investors in AngioDynamics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various AngioDynamics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's per employee growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of AngioDynamics per employee as a starting point in their analysis.

Net Income Per Employee


AngioDynamics Net Income Per Employee is very stable at the moment as compared to the past year. AngioDynamics reported last year Net Income Per Employee of (40,169.5)

Revenue Per Employee


AngioDynamics Revenue Per Employee is very stable at the moment as compared to the past year. AngioDynamics reported last year Revenue Per Employee of 374,470
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AngioDynamics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. To learn how to invest in AngioDynamics Stock, please use our How to Invest in AngioDynamics guide. Note that the AngioDynamics information on this page should be used as a complementary analysis to other AngioDynamics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.

Complementary Tools for AngioDynamics Stock analysis

When running AngioDynamics' price analysis, check to measure AngioDynamics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AngioDynamics is operating at the current time. Most of AngioDynamics' value examination focuses on studying past and present price action to predict the probability of AngioDynamics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AngioDynamics' price. Additionally, you may evaluate how the addition of AngioDynamics to your portfolios can decrease your overall portfolio volatility.
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Is AngioDynamics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AngioDynamics. If investors know AngioDynamics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AngioDynamics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
Revenue Per Share
Quarterly Revenue Growth
Return On Assets
Return On Equity
The market value of AngioDynamics is measured differently than its book value, which is the value of AngioDynamics that is recorded on the company's balance sheet. Investors also form their own opinion of AngioDynamics' value that differs from its market value or its book value, called intrinsic value, which is AngioDynamics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AngioDynamics' market value can be influenced by many factors that don't directly affect AngioDynamics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AngioDynamics' value and its price as these two are different measures arrived at by different means. Investors typically determine if AngioDynamics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AngioDynamics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.